Brain Cancer Trial, Recruiting NCT07657403 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07657403
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with a brain tumor located near areas of the brain involved in language, movement, or major brain communication networks.
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scoring tool called the Karnofsky Performance Status (KPS), with a score of 70 or higher.
  • People whose pre-surgery MRI scan shows that the tumor is close to important nerve pathways in the brain, such as those involved in movement or language.
  • People who do not have any other neurological disease or condition that could itself cause problems with brain function.
  • People who have not previously received treatment, such as radiotherapy, for a brain tumor in the same area of the brain.
  • People whose tumor is not extensively attached to multiple critical brain network areas.
  • People who are already planning to have surgery to remove the brain tumor and who are able to provide written agreement to take part (or whose legal representative can do so on their behalf).

Who may not be able to join:

  • People whose brain lesion is suspected or confirmed to be something other than a tumor (for example, a non-cancerous or inflammatory condition).
  • People who have tumors in more than one separate location in the brain.
  • People whose medical evaluation records are incomplete.
  • People, or their legal representatives, who choose to withdraw from the study for any reason.
  • People who are pregnant, breastfeeding, possibly pregnant, or planning to become pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8618888294650

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Postoperative Functional Preservation Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov